Name | PTP1B-IN-2 |
Description | PTP1B-IN-2 is an effective protein tyrosine phosphatase 1B (PTP1B) inhibitor(IC50=50 nM). |
Kinase Assay | The PTP1B enzymatic assay, the total volume of 100 μL per well contains15 nM recombinant PTP1B protein, 2 mM p-nitrophenylphosphonic acid (pNPP), 1 mM dithiothreitol and 1 mM EDTA (pH 6.5). After 30 min incubation at 37℃, end the reaction by addition of 2.5 M NaOH. The hydrolysis product, pNP, is detected at the absorbance at 405 nm. |
In vitro | PTP1B-IN-2 extends deep into the active site pocket, forming several hydrogen bonds and hydrophobic interactions with key residues of the catalytic site. PTP1B-IN-2 greatly enhances insulin-mediated IRβ phosphorylation at concentrations of 15 μM and 30 μM. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 45 mg/mL (66.1 mM)
|
Keywords | PTP1B-IN-2 | Inhibitor | PTP-1B-IN-2 | inhibit | PTP1BIN2 | Phosphatase | PTP1B IN 2 |
Inhibitors Related | PTP1B-IN-22 | Disodium monofluorophosphate | β-Glycerophosphate disodium salt pentahydrate | MLS000544460 | Tartaric acid disodium dihydrate | Cyclosporine | Stearic acid | Cis-5-Norbornene-exo-2,3-dicarboxylic Anhydride | L-Ascorbic acid 2-phosphate magnesium | Cyclosporin A | Trimyristin | β-Glycerophosphate disodium salt hydrate |
Related Compound Libraries | Glycometabolism Compound Library | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Inhibitor Library | NO PAINS Compound Library | Metabolism Compound Library | Bioactive Compounds Library Max | Anti-Metabolism Disease Compound Library | Anti-COVID-19 Compound Library | Phosphatase Inhibitor Library |